Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Given $115.00 Consensus Target Price by Brokerages

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a 12 month consensus target price of $115.00 for the company and are anticipating that the company will post $1.96 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Taro Pharmaceutical Industries an industry rank of 87 out of 256 based on the ratings given to related companies.

Several equities analysts have recently weighed in on TARO shares. TheStreet lowered ZovioInc . from a “c-” rating to a “d” rating in a research note on Thursday, May 23rd. ValuEngine lowered Verso from a “hold” rating to a “sell” rating in a research note on Thursday, May 23rd. Finally, Zacks Investment Research lowered Essential Properties Realty Trust from a “buy” rating to a “hold” rating in a research note on Thursday, June 13th.

Shares of NYSE TARO traded down $0.62 during midday trading on Tuesday, hitting $83.56. The stock had a trading volume of 52,309 shares, compared to its average volume of 72,177. The company has a market cap of $3.22 billion, a P/E ratio of 11.56 and a beta of 0.48. Taro Pharmaceutical Industries has a 1-year low of $76.93 and a 1-year high of $117.56. The business has a fifty day moving average of $87.17.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings data on Wednesday, May 22nd. The company reported $1.52 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.74). The firm had revenue of $179.92 million during the quarter, compared to analyst estimates of $189.90 million. Taro Pharmaceutical Industries had a net margin of 42.06% and a return on equity of 13.44%. On average, analysts expect that Taro Pharmaceutical Industries will post 8.98 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Enterprise Financial Services Corp purchased a new stake in shares of Taro Pharmaceutical Industries during the 1st quarter valued at about $44,000. American National Insurance Co. TX purchased a new stake in shares of Taro Pharmaceutical Industries during the 1st quarter valued at about $224,000. ELCO Management Co. LLC purchased a new stake in shares of Taro Pharmaceutical Industries during the 1st quarter valued at about $230,000. Two Sigma Advisers LP raised its holdings in shares of Taro Pharmaceutical Industries by 12.5% during the 4th quarter. Two Sigma Advisers LP now owns 2,700 shares of the company’s stock valued at $229,000 after buying an additional 300 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter valued at about $239,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Featured Article: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Taro Pharmaceutical Industries (TARO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit